The mean of analysts' price targets for Arcutis Biotherapeutics (ARQT) points to a 25.8% upside in t

WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq:

WESTLAKE VILLAGE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq:

Biotech stock Arcutis is in a buy zone and Wall Street is looking for the skin-diseases drugmaker to

FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Applicat

FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027 Applica

Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how e

WESTLAKE VILLAGE, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq:

Virtual health platform offers an additional pathway to care for the more than 45 million people in

ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque p

ZORYVE cream 0. 3% is the first once-daily, non-steroidal therapy approved for children with plaque

Arcutis Biotherapeutics NASDAQ: ARQT executives said ZORYVE continues to post strong growth and outl

Arcutis Biotherapeutics, Inc. (ARQT) Presents at Goldman Sachs 47th Annual Global Healthcare Confere

WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq:

Expert recommendations focused on the diagnosis and management of genital psoriasis across age group

Expert recommendations focused on the diagnosis and management of genital psoriasis across age group

Arcutis today announced that management will present at the Goldman Sachs 47th Annual Global Healthc

Arcutis Biotherapeutics (ARQT) is evolving into a specialized dermatology platform, leveraging ZORYV

WESTLAKE VILLAGE, Calif. , May 08, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: A

Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and ma

Arcutis Biotherapeutics, Inc. (ARQT) Q1 2026 Earnings Call Transcript

Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $0.09 per share versus the Za

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.09) per share which missed th

Submission supported by data from INTEGUMENT-INFANT Phase 2 open-label study in infants aged 3 month

Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety,

Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent

  On Tuesday, 647 companies set new 52-week lows.

  On Monday, 369 companies set new 52-week lows.

  During the session on Thursday, 461 stocks hit new 52-week lows.

  During Wednesday's session, 212 companies made new 52-week lows.

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn